US FDA Advances Drug Research: The Role of Organoids and AI in Reducing Animal Testing
The US Food and Drug Administration (FDA) is making strides to minimize animal testing in drug research by promoting technologies like human organoids, organs-on-chips, and artificial intelligence. This transition, part of an initiative from the US Department of Health and Human Services (HHS), aims to adopt methodologies that better reflect human biology.
On September 21, the FDA announced updated regulations, permitting the use of non-animal methods for drug safety assessments prior to human trials. Acting Commissioner Kyle Diamantas stated that while animal studies retain their place, the focus will broaden to include alternatives, enhancing predictive capacities regarding medicines' effects on humans.
Why Is FDA Moving Away From Animal-Based Studies?
For decades, animal testing has been integral to drug development. However, discrepancies in biological responses between species highlight the limitations of this approach. The FDA's new strategy embraces New Approach Methodologies (NAMs)—comprehensive laboratory and computational methods designed to deliver more precise evidence without primarily relying on animal testing.
Organoids May Replace Some Animal Experiments
Organoids, which are three-dimensional cell cultures derived from human stem cells, can mimic organ structures and functions. This technology allows for the examination of human cellular responses to experimental drugs, leading to more relevant insights.
What Are Organs-On-Chips?
Organs-on-chips, or microphysiological systems, are pioneering devices that replicate the environment of human organs using cellular structures. They provide researchers with controlled settings to test the effects of drugs, such as potential liver toxicity.
AI & Computational Models
Investments in artificial intelligence and computational models allow for the analysis of extensive biological data, enhancing predictive capabilities regarding drug behavior in human systems. Though the FDA's new rule encourages the adoption of innovative methods, it still supports traditional animal studies when necessary.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.